Oxford Immunotec Global Plc Quick Ratio (OXFD) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Oxford Immunotec Global Plc  (NASDAQ: OXFD)

Oxford Immunotec Global Plc's Quick Ratio

OXFD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2020, Quick Ratio fell to 13.61 above Oxford Immunotec Global Plc average.

Within In Vitro & In Vivo Diagnostic Substances industry only one company has achieved higher Quick Ratio in third quarter 2020. While Quick Ratio total ranking in the third quarter 2020 has deteriorated compared to the prior quarter from 205 to 300.

Explain Quick Ratio?
How much Cash & cash equivalents OXFD´s has?
What are OXFD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OXFD Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change -29.45 % -35.37 % -18.98 % -0.6 % -65.49 %
Y / Y Cash & cash equivalent Change -12.84 % -11.64 % -12.15 % -6 % 162.67 %
Quick Ratio MRQ 13.61 15.31 11.86 13.12 11.02
OXFD's Total Ranking # 300 # 205 # 40 # 156 # 226
Seq. Current Liabilities Change 9.15 % -22.95 % 1.54 % -17.39 % -0.01 %
Seq. Cash & cash equivalent Change -2.94 % -0.6 % -8.16 % -1.63 % -1.61 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 139
Overall Market # 300


Quick Ratio Statistics
High Average Low
15.31 7.42 1.45
(Jun 30 2020)   (Sep 30 2018)




Financial Statements
Oxford Immunotec Global Plc's Current Liabilities $ 12 Millions Visit OXFD's Balance sheet
Oxford Immunotec Global Plc's Cash & cash equivalent $ 161 Millions Visit OXFD's Balance sheet
Source of OXFD's Sales Visit OXFD's Sales by Geography


Cumulative Oxford Immunotec Global Plc's Quick Ratio

OXFD's Quick Ratio for the trailling 12 Months

OXFD Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth -21.98 % -42.55 % -34.62 % -29.37 % -28.96 %
Y / Y Cash & cash equivalent TTM Growth -10.62 % 9.02 % 38.66 % 82.62 % 148.01 %
Quick Ratio TTM 13.35 12.59 11.73 11.49 11.66
Total Ranking TTM # 3754 # 3794 # 3847 # 3746 # 3876
Seq. Current Liabilities TTM Growth -8.89 % -9.65 % -5.09 % -0.13 % -32.92 %
Seq. Cash & cash equivalent TTM Growth -3.39 % -3.03 % -3.1 % -1.54 % 17.84 %

Quick ratio ranking by company, industry and sector >> Back to OXFD Financial Strength Comparisons >> Go to Compare OXFD Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Oxford Immunotec Global Plc's average Cash & cash equivalent, this led to increase in in Oxford Immunotec Global Plc's Quick Ratio to 13.35, above OXFD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 19 other companies have achieved higher Quick Ratio than Oxford Immunotec Global Plc. While Quick Ratio overall ranking has improved so far to 3754, from total ranking during the twelve months ending second quarter 2020 at 3794.

Explain Quick Ratio?
How much Cash & cash equivalents OXFD´s has?
What are OXFD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 20
Healthcare Sector # 847
Within the Market # 3754


trailing twelve months Quick Ratio Statistics
High Average Low
13.35 6.49 2.62
(Sep 30 2020)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Celldex Therapeutics inc   16.36 $ 199.594  Millions$ 12.200  Millions
Oxford Immunotec Global Plc  13.61 $ 160.621  Millions$ 11.801  Millions
Achieve Life Sciences Inc   12.12 $ 22.393  Millions$ 1.848  Millions
Qc Technologies Inc   9.19 $ 23.119  Millions$ 2.515  Millions
Neogen Corporation  7.91 $ 367.486  Millions$ 46.442  Millions
Intellia Therapeutics Inc   7.30 $ 407.947  Millions$ 55.865  Millions
Volitionrx Limited  4.85 $ 20.928  Millions$ 4.318  Millions
Biomerica Inc   3.87 $ 6.964  Millions$ 1.801  Millions
Quotient Limited  3.74 $ 162.743  Millions$ 43.537  Millions
Immucell Corporation  3.28 $ 5.911  Millions$ 1.802  Millions

Date modified: 2026-09-08T15:10:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.